Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
7.17
-0.16 (-2.17%)
Aug 14, 2025, 11:23 AM - Market open
Company Description
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts.
Jade Biosciences, Inc.
| Country | United States |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Tom Frohlich |
Contact Details
Address: 221 Crescent Street Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 916 322 1700 |
| Website | jadebiosciences.com |
Stock Details
| Ticker Symbol | JBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000947559 |
| CUSIP Number | 008064206 |
| ISIN Number | US0080642061 |
| Employer ID | 64-0862173 |
| SIC Code | 6021 |
Key Executives
| Name | Position |
|---|---|
| Tom Frohlich | Chief Executive Officer and Director |
| Bradford D. Dahms Ph.D. | Chief Financial Officer |
| Dr. Andrew James King D.V.M., Ph.D. | Chief Scientific Officer and Head of Research & Development |
| Elizabeth Balta | General Counsel and Corporate Secretary |
| Lori Stewart | Senior Vice President of People |
| Dr. Hetal Kocinsky M.D. | Chief Medical Officer |
| Dr. Jason Wright Ph.D. | Senior Vice President, Chemistry, Manufacturing and Controls |
| Jonathan Quick | Senior Vice President of Finance |
| Valerie Fauvelle | Senior Vice President of Regulatory and Quality |
| Amy Sullivan | Senior Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | SCHEDULE 13G/A | Filing |
| Apr 17, 2025 | 15-12G | Securities registration termination |
| Apr 17, 2025 | 15-12G | Securities registration termination |
| Apr 9, 2025 | EFFECT | Notice of Effectiveness |
| Apr 9, 2025 | EFFECT | Notice of Effectiveness |
| Apr 8, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 8, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |